{"id":534683,"date":"2010-04-19T13:59:19","date_gmt":"2010-04-19T17:59:19","guid":{"rendered":"tag:www.hepatitis-central.com,2010:\/mt\/\/1.810"},"modified":"2010-04-19T14:02:12","modified_gmt":"2010-04-19T18:02:12","slug":"experimental-polymerase-inhibitor-lowers-hcv-viral-load-fast","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/534683","title":{"rendered":"Experimental Polymerase Inhibitor Lowers HCV Viral Load Fast"},"content":{"rendered":"<p>After just three days of a Phase 1b trial, Vertex&#8217;s VX-222 is asserting itself as a possible contender to partner with telaprevir for a new Hepatitis C combination therapy regimen.<\/p>\n<p>Hepatitis C Virus Polymerase Inhibitor VX-222 Reduced Viral Levels Over Three Days In Phase 1b Trial<\/p>\n<p>In conjunction with an oral presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from a Phase 1b clinical trial of the investigational oral hepatitis C virus (HCV) polymerase inhibitor, VX-222. In the trial, treatment with VX-222 for three days was well-tolerated, with all adverse events being mild to moderate in severity. <\/p>\n<p>Continue reading this entire article:<br \/>\n<a href=\"http:\/\/www.thestreet.com\/story\/10726924\/1\/hepatitis-c-virus-polymerase-inhibitor-vx-222-reduced-viral-levels-over-three-days-in-phase-1b-trial.html?cm_ven=GOOGLEFI\">http:\/\/www.thestreet.com\/story\/10726924\/1\/hepatitis-c-virus-polymerase-inhibitor-vx-222-reduced-viral-levels-over-three-days-in-phase-1b-trial.html?cm_ven=GOOGLEFI<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>After just three days of a Phase 1b trial, Vertex&#8217;s VX-222 is asserting itself as a possible contender to partner with telaprevir for a new Hepatitis C combination therapy regimen. Hepatitis C Virus Polymerase Inhibitor VX-222 Reduced Viral Levels Over Three Days In Phase 1b Trial In conjunction with an oral presentation at the 45th [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-534683","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/534683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=534683"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/534683\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=534683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=534683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=534683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}